
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value…
Read report ↗





